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Abstract 
Adams-Oliver syndrome (AOS) is a rare developmental disorder characterized by the presence of 
aplasia cutis congenita (ACC) of the scalp vertex and terminal limb reduction defects. Cardiovascular 
anomalies are also frequently observed. Mutations in five genes have been identified as a cause for 
AOS prior to this report. Mutations in EOGT and DOCK6 cause autosomal recessive AOS, whereas 
mutations in ARHGAP31, RBPJ and NOTCH1 lead to autosomal dominant AOS. As RBPJ, NOTCH1 and 
EOGT are involved in NOTCH signaling, we hypothesized that mutations in other genes involved in 
this pathway may also be implicated in AOS pathogenesis. Using a candidate gene based approach, 
we prioritized DLL4, a critical NOTCH ligand, due to its essential role in vascular development in the 
context of cardiovascular features in AOS individuals. Targeted resequencing of the DLL4 gene using a 
custom enrichment panel in 89 independent families resulted in the identification of 7 mutations. A 
defect in DLL4 was also detected in two pedigrees with whole exome/genome sequencing. In total, 
nine heterozygous mutations in DLL4 were identified, including two nonsense and seven missense 
variants, the latter encompassing four mutations that replace or create cysteine residues, which are 
likely critical for maintaining structural integrity of the protein. Affected individuals with DLL4 
mutations present with variable clinical expression with no emerging genotype-phenotype 
correlations. Our findings demonstrate that DLL4 mutations are an additional cause of autosomal 
dominant AOS or isolated ACC and provide further evidence for a key role of NOTCH signaling in the 
etiology of this disorder.  
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Adams-Oliver syndrome (AOS [MIM100300]) is a rare developmental disorder with an estimated 
incidence of 1 in 225,000 live births.1 It is typically characterized by the presence of both aplasia cutis 
congenita (ACC) of the scalp vertex and terminal limb defects, such as brachydactyly, oligodactyly, 
syndactyly, hypoplastic nails or transverse amputations.2 In addition, vascular and cardiac anomalies, 
comprising pulmonary hypertension, ventricular septum defects, tetralogy of Fallot and anomalies of 
the great arteries and their valves are frequently observed.2 In the past few years, mutations in five 
genes have been described as a cause of AOS. Mutations in EOGT (MIM 615297) and DOCK6 (MIM 
614219) cause the autosomal recessive form of AOS, while mutations in ARHGAP31 (MIM 100300), 
RBPJ (MIM 614814) and NOTCH1 (MIM 616028) lead to the autosomal dominant form of AOS.3-8 
NOTCH1, EOGT, and RBPJ are all members of the NOTCH signaling pathway. This pathway is 
conserved throughout metazoan species and involved in many different tissue specific cellular 
processes, including cell-fate determination and neural and hematopoietic stem cell differentiation.9; 
10 The NOTCH receptors and ligands are composed of several domains, including epidermal growth 
factor (EGF)-like domains. EOGT is an EGF domain-specific O-linked N-acetylglucosamine (GlcNAc) 
transferase known to glycosylate NOTCH1 and is therefore highly likely to influence NOTCH signaling 
through post-translational modification of the extracellular EGF-like repeats.4; 10; 11 RBPJ is a sequence 
specific transcription factor that regulates the transcriptional activity of downstream target genes by 
binding to the intracellular domain of NOTCH, leading to the recruitment of additional proteins.12 
Besides AOS, mutations in NOTCH1 are also known to cause bicuspid aortic valve and thoracic aortic 
aneurysm.13 NOTCH signaling is activated by two families of ligands, namely Jagged (JAG1 or -2) and 
Delta (DLL1, -3 or -4). Of these, DLL4 has an essential role in vascular development and angiogenesis, 
which places it as a prime candidate for AOS, due to the presence of cardiovascular features in AOS 
individuals.14; 15  
 
The study was approved by the appropriate institutional review board (IRB) and appropriate 
informed consents were obtained from human subjects. We performed targeted resequencing of 
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DLL4 on 89 individuals using HaloPlex Targeted Enrichment (Agilent Technologies) followed by 
sequencing on MiSeq (Illumina) using 2 x 150 bp paired end reads. An in-house developed Galaxy-
based pipeline was used to process the raw data.16 Variant calling was performed using the GATK 
Unified Genotyper17 and variants were annotated and filtered using the in-house developed 
database, VariantDB.18 Unique variants (ESP6500 and 1000 Genomes project) were selected, 
prioritizing nonsense, nonsynonymous, splice site, and indel variants in both a dominant and a 
recessive model.  
Separately, whole genome sequencing (WGS) was performed on family 2 and whole exome 
sequencing (WES) was performed on family 6. Genomic DNA was extracted from saliva from the two 
affected siblings of family 2, and subjected to the Agilent SureSelect Target Enrichment (v4; 51 Mb) 
capture process. Following library preparation, sequencing was performed on the Illumina 
HiSeq2000, generating 100 bp paired end reads. Over 97.5% of target regions were covered by >10X 
reads. Reads were mapped against reference genome UCSC hg19 with BWA. Single nucleotide 
variants and indels were detected by SAMTOOLS. WES on family 6 was performed as previously 
described.7 All variants were confirmed by bidirectional Sanger sequencing and segregation analysis 
was performed on available family members.  
In total, we screened 91 families and identified nine heterozygous variants in DLL4 (RefSeq transcript 
NM_019074.3, with GRCh37 as a reference build), including nonsense, cysteine replacing or creating 
and other missense substitutions (Figure 1, Table S1). These results designate mutations in this gene 
as an additional cause of an autosomal dominant form of AOS.  
 
In two families, we detected nonsense mutations in exon 9 of DLL4, specifically c.1660C>T 
(p.Gln554*; ClinVar accession number SCV000240088) in family 1 and c.1672C>T (p.Arg558*; ClinVar 
SCV000240089) in family 2. Both stopgain mutations are predicted to lead to nonsense mediated 
decay (NMD) of the mutant mRNA transcript (Figure 1B).19 The severity of the clinical features in the 
affected family members of both families varied widely and included ACC, syndactyly and 
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brachydactyly (Figure 2, Table 1). In the proband of family 1 (1-III-3), cardiovascular features were 
also present, namely tricuspid insufficiency and ventricular septum defect (Table 1). Molecular 
screening of available family members of family 1 showed segregation of the mutation in the 
affected sister (1-III-1) and mother (1-II-2), and absence of the mutation from the unaffected father 
(1-II-1) and maternal grandmother (1-I-2). Interestingly, the mutation was not detected in the 
maternal grandfather (1-I-1), who presented with unilateral brachydactyly of the toes (III and IV). We 
failed to demonstrate the possibility of somatic mosaicism in his blood by a mutation allele specific 
PCR. Nevertheless, somatic mosaicism not affecting the hematopoietic tissue remains a plausible 
explanation. In family 2, the affected sister (2-II-1) also carried the mutation. Mutation analysis of the 
parents showed that c.1672C>T was inherited from their father (2-I-1) who did not show obvious 
signs of AOS. DNA of the paternal grandparents was not available to investigate whether the 
mutation in the father occurred de novo.  
In addition to the two stopgain mutations, we identified seven different heterozygous missense 
mutations: three cysteine replacing mutations, one cysteine creating mutation and three other 
missense mutations. All identified missense mutations were predicted to be damaging by 
MutationTaster, PolyPhen-2 and SIFT and none of the mutations were present in the following public 
databases: ESP6500, Kaviar,20 1000 Genomes Project and ExAC database.  
In families 3, 4 and 5, cysteine replacing mutations (c.1365C>G, p.Cys455Trp [ClinVar 
SCV000240090]; c.1169G>A, p.Cys390Tyr [ClinVar SCV000240091]; c.1168T>C, p.Cys390Arg [ClinVar 
SCV000240092], respectively) in exons 8 and 9 of DLL4 were identified. All of these mutations affect 
critical and highly conserved (up to D. melanogaster) cysteines of the consensus sequence of either 
the 5th or 7th EGF-like domain (Figure 1C). Similar to the nonsense mutations, the severity of the 
clinical features of all available affected family members varied greatly, but all showed scalp 
involvement, including ACC or a bald scalp area (Table 1, Figure 2). The c.1365C>G (p.Cys455Trp) 
mutation, identified in the proband of family 3 (3-II-1), was confirmed in the affected mother (3-I-2) 
and in a sister (3-II-2), but no clinical information of the latter was available. In both family 4 
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(c.1169G>A, p.Cys390Tyr) and family 5 (c.1168T>C, p.Cys390Arg), we found a mutation replacing the 
cysteine residue at position 390 but leading to different amino acid substitutions. The proband of 
family 4 (4-II-1) showed isolated ACC and no family members were available for screening. The 
proband of family 5 (5-IV-3) is part of a large family with multiple affected individuals. The father (5-
III-3) and two great aunts (5-II-14, 5-II-17)  carried the c.1168T>C mutation (Figure 1A). They were all 
only mildly affected, but did have severely affected offspring (Table 1, Figure 2), further illustrating 
the highly variable clinical expression for DLL4 associated AOS.  
In the proband of family 6 (6-II-1) we detected a heterozygous cysteine creating mutation: c.556C>T 
(p.Arg186Cys; ClinVar SCV000240093). The affected family members both exhibited isolated ACC 
(Table 1, Figure 2). The arginine at this position is conserved between DLL4 and DLL3 and is 
conserved across mammalian species (Figure 1C). The affected father (6-I-1) carried the mutation, 
while the unaffected mother (6-I-2) did not.  
In families 7, 8 and 9, we found missense variants (c.799C>A, p.Pro267Thr [ClinVar SCV000240094]; 
c.361G>C, p.Ala121Pro [ClinVar SCV000240095]; c.583T>C, p.Phe195Leu [ClinVar SCV000240096], 
respectively) affecting specific residues in functional domains of DLL4 which are conserved up to D. 
melanogaster and in the four most closely related ligands of the NOTCH receptors, namely JAG1, 
JAG2, DLL1 and DLL4 (Figure 1C). Both families 7 and 8 presented with scalp defects, limb defects and 
cardiovascular features (Table 1, Figure 2). The parents of proband 7 were reported as unaffected, 
but the mother (7-I-2), who was a mutation carrier, has a positive family history for cardiac events 
with a brother with bicuspid aortic valve with narrowed aorta ascendens and a maternal half-brother 
who died at birth of an unspecified heart defect. Unfortunately, DNA of the maternal grandparents 
or other family members was not available. In the proband of family 8 (8-II-1) the c.361G>C 
(p.Ala121Pro) mutation was shown to be de novo, as both unaffected parents did not carry the 
mutation (Figure 1A). The index of family 9 has been described before and shows only aplasia cutis 
congenita.21 In this individual we identified a heterozygous c.583T>C (p.Phe195Leu) variant. No 
further information of familial occurrence was available. 
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The DLL4 variants are distributed across the complete protein, affecting all known structural domains 
(MNNL [N-terminal domain of NOTCH ligands], DSL [Delta/Serrate/Lag-2] and EGF-like domains), 
without any obvious mutational hotspots. Recently, the structural basis of the interaction between 
NOTCH1 and DLL4 has been elaborated. 10 The binding of NOTCH1 to DLL4 is coordinated by the 
interaction between the NOTCH1 EGF-like 11 and the DLL4 DSL domain. DLL4-NOTCH1 binding is 
further modulated by the interaction between NOTCH1 EGF-like 12 and the MNNL domain of DLL4. 
Glycosylation of NOTCH1 is essential and specific for the binding of DLL4.10 
Three-dimensional modeling predictions of our DLL4 mutations reveals interesting changes in protein 
conformation and amino acid functionality (Figure S1). In total, three cysteine replacing mutations 
have been found, two at position 390 (p.Cys390Arg and p.Cys390Tyr), located in EGF-like domain 5 
and one at position 455 (p.Cys455Trp), located in the 7th EGF-like domain. All three cysteines are 
involved in the formation of a disulfide bond in their respective EGF-domain, which will be lost due to 
the introduction of these mutations. Furthermore, both arginine and tyrosine residues at position 
390 are too bulky to fit in this domain and are therefore likely to disrupt the structure. Hence, 
structural changes are predicted to occur, which will most likely lead to a loss of function of DLL4.  
Both phenylalanine at position 195 and arginine at position 186 are located in the DSL domain of 
DLL4 (Figure 1B),  a conserved central domain directly involved in ligand binding to the 11th EGF-like 
domain of the NOTCH1 receptor.10 It has been shown that the phenylalanine at position 195 is a key 
interface residue important for binding and when mutated to an alanine residue it results in a 
substantial decrease in NOTCH1 interaction.10 The p.Arg186Cys mutation is located in the surface 
loop of the DSL domain. The introduction of a cysteine at this location is not expected to cause steric 
hindrance; however, the important interaction function of the Arginine186 residue is likely to be lost. 
In addition, this mutation creates a cysteine, which could dramatically alter the conformation of the 
protein by forming a novel disulfide bond. Both these DSL domain mutations will likely reduce the 
binding affinity of DLL4 to NOTCH1. 
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The Alanine121 residue is located in a beta-strand on the inside of the MNNL domain. Together with 
the DSL domain, the MNNL domain is involved in the binding of the ligand to EGF-like domain 12 of 
the NOTCH-receptor and regulates ligand pleiotropy.10 The replacement of Alanine 121 by proline is 
predicted to disrupt the local structure and function. Lastly, the Proline267 residue is located in EGF-
like domain 2 and makes contact with EGF-like domain 1 in a surface loop. This interaction might be 
altered by the substitution to threonine.  
 
The discovery of DLL4 mutations in our AOS individuals in addition to prior identification of mutations 
in EOGT, RBPJ and NOTCH1, confirms the key role of the NOTCH signaling pathway in the 
pathogenesis of AOS. Activation of NOTCH signaling through binding of a NOTCH-ligand (JAG1, JAG2, 
DLL1, DLL3, DLL4) to one of the NOTCH receptors (1 to 4), results in two proteolytic cleavage 
reactions performed by a member of the ADAM (A Disintegrin and metalloproteinase domain-
containing protein) family and by the ү-secretase complex. The second cleavage releases the 
intracellular domain of NOTCH (NICD), which is translocated to the nucleus, where it binds to the 
coactivator Mastermind Ligand (MAML) and the DNA binding protein RBPJ to induce transcription of 
NOTCH target genes.22 
DLL4 is a ligand of the NOTCH receptors and is essential for vascular development.12 During 
embryonic development, protein localization of DLL4 is restricted to the large arteries, while in adult 
stages protein levels are found in the smaller arteries and microvessels. Haploinsufficiency of Dll4 in 
mice results in embryonic lethality due to profound defects in vascular and arterial development.15 In 
contrast to mice models, human haploinsufficiency of DLL4 does not result in lethality as we have 
identified two heterozygous nonsense mutations, which most likely lead to NMD.19 The lethality in 
mice could be related to the inbred genetic background of the mice23 and potential functional 
differences in redundancy between humans and mice. The identification of both DLL4 nonsense 
mutations and several missense mutations in key functional domains of DLL4 that are predicted to 
disrupt DLL4 integrity, suggests that loss-of-function is the pathogenetic mechanism. While DLL4 is 
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described to be essential for vascular development12, not all individuals with DLL4 mutations 
presented with cardiovascular features (Table 1), although complete cardiovascular exams have not 
been performed in all cases.  
We did not observe a clear genotype-phenotype correlation between DLL4 mutation and AOS 
subtype. Furthermore, we observed marked intrafamilial variability in the phenotypic expression. For 
example, in family 5 the p.Cys390Arg substitution leads to a severe phenotype in the offspring, while 
the parents show isolated ACC. This suggests that other factors are involved in the clinical expression 
of this disease, which could be environmental factors, but also other genetic and epigenetic 
influences involved in the NOTCH signaling pathway or other AOS related pathways. In addition to 
the variable clinical expression, we also observed incomplete penetrance in families 2 and 7, and 
additional unidentified asymptomatic mutation carriers may exist in other families. Highly variable 
expressivity and incomplete penetrance, as well as the association with cardiovascular abnormalities 
are similar to what has been observed in NOTCH1-related AOS.7; 8 In contrast, cerebral and ocular 
abnormalities which have been found to be particularly associated with autosomal recessive DOCK6 
related AOS appear to be uncommon in those autosomal dominant forms. 24 
 
In conclusion, through screening a cohort of 91 families affected with Adams-Oliver syndrome or 
aplasia cutis congenita, we have identified nine heterozygous variants in DLL4, including nonsense, 
cysteine replacing or creating and other missense mutations, demonstrating that mutations in this 
gene are an important cause of autosomal dominant AOS or isolated ACC. Affected individuals show 
variable clinical expression with at present no clear genotype-phenotype correlations. With the 
addition of DLL4, four genes involved in NOTCH signaling have now been implicated in AOS, 
confirming that disruption of this pathway plays a major role in the pathogenesis of AOS. 
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Table 1 Clinical features 
Individual 
Internal 
reference 
Mutation 
status 
Clinical features 
Scalp defects Limb defects Cardiovascular features Other remarks 
1-I-1 SK039 - / 
Left brachydactyly of 3rd and 4th toe 
(confirmed by X-ray) 
/ / 
1-II-2 SK039 + / Short distal phalanges (not confirmed by X-ray) / / 
1-III-1 SK039 + ACC / Normal echocardiogram  / 
1-III-3 SK039 + ACC Brachydactyly, syndactyly of 2nd and 3rd toe on right foot 
Tricuspid insufficiency, 
ventricular septum defect 
/ 
2-II-1 F45 + ACC with underlying skull defect Brachydactyly left foot; missing toes right foot Normal echocardiogram / 
2-II-3 F45 + ACC with underlying skull defect Brachysyndactyly right foot; severe brachysyndactyly left foot Normal echocardiogram Small kidneys; mild hypertension 
3-I-2 SK038 + ACC / / / 
3-II-1 SK038 + ACC / / / 
4-II-1 SK049 + ACC / / / 
5-II-4 SK087 No DNA ACC 
Syndactyly of 2nd and 3rd toe, hypoplastic toe nails, 
brachydactyly of toes 
/ / 
5-II-14 SK087 + Bald area on scalp / / Cutis marmorata 
5-II-17 SK087 + Bald area on scalp Brachydactyly of fingers and toes, syndactyly of 2nd and 3rd toe / / 
5-III-3 SK087 + Bald area on scalp / / / 
5-III-21 SK087 No DNA Bald area on scalp / / / 
5-III-23 SK087 No DNA ACC with underlying skull defect / / / 
5-IV-3 SK087 + ACC / Normal echocardiogram 
Cutis marmorata, epilepsy, learning difficulties, borderline 
intellectual function (TIQ 76) at young age, normal IQ at later age, 
mild periventricular leukomalacia 
5-IV-12 SK087 No DNA ACC / 
Normal echocardiogram, 
portal hypertension, 
esophageal varices 
Splenomegaly, congenital liver fibrosis 
6-I-1 UK16 + ACC / No cardiac problems / 
6-II-1 UK16 + ACC / Normal echocardiogram / 
7-I-2 SK082 + / / / Unaffected 
7-II-1 SK082 + ACC, delayed ossification Hypoplastic toe nails No cardiac problems Cutis marmorata, normal chest X-ray at age two months 
8-II-1 SK081 + ACC 
Short distal phalangus of middle finger of the right hand, 
symphalangism of the index finger, symbrachydactyly of both 
feet (front and middle foot missing on right foot) 
Truncus arteriosus, 
ventricular septum defect 
Growth hormone deficiency 
9-II-1 SK013 + ACC / / / 
The following abbreviations are used: ACC, Aplasia Cutis Congenita; /, unknown 
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Figure 1. Mutation analysis  
(A) Pedigrees of the families with their respective mutation and nucleotide sequence.  
(B) Structure of DLL4 with the structural domains and the identified mutations.  
(C) Conservation of specific residues amongst species and NOTCH ligands. 
 
Figure 2. Clinical features 
(A) Individual 2-II-1 with brachydactyly of left foot and missing toes right foot.  
(B) Individual 5-II-17 with a bald area on the scalp.  
(C) Individual 5-II-17 with brachydactyly of toes.  
(D) Individual 5-II-17 with brachydactyly of fingers.  
(E) Individual 5-IV-12 with aplasia cutis congenita.  
(F) Individual 6-II-1 with aplasia cutis congenita.  
(G) Individual 8-II-1 with short distal phalangus of middle finger and symphalangism of the index 
finger of the right hand.  
(H) Individual 8-II-1 with aplasia cutis congenita.  
(I) Individual 8-II-1 with symbrachydactyly of both feet (front and middle foot missing on right foot). 
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